Synthesis and in vitro anti-HIV screening of certain 2-(benzoxazol-2-ylamino)-3H-4-oxopyrimidines

Scientia Pharmaceutica

Volumn 71, Issue 2, 2003, Pages 57-74

  Rostom, Sherif A F ^a   Fahmy, Hesham T Y ^c   Saudi, Manal N S ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Alexandria University Faculty of Pharmacy   (Egypt)

^c NONE

Author keywords

AIDS; Anti HIV screening; Benzoxazoles; HIV; Pyrimidines

Indexed keywords

2 (BENZOXAZOL 2 YLAMINO) 6 HYDROXY 3H 4 OXOPYRIMIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NSC 722448; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CHEMICAL REACTION; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INFRARED SPECTROSCOPY; MELTING POINT; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS;

EID: 0037599495     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.aut-03-08     Document Type: Article

References (27)

1. Barre-Sinoussi F., Cherman J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rosenbaum W., Montagnier M. (1983), Science 220: 868.
2. Esparsa J. (2001), Bull. WHO 79: 1133.
3. Nagelkerke N. J. D., Iha P., de Vals S. J., Korenromp E. L., Moses S., Blanchard J. F., Plummer F. A. (2002), Bull. WHO 80: 89.
4. Hoegberg M., Sahlberg C., Engelhardt P., Noreen R., Kangasmetsae J., Johannson N. G., Oeberg B., Vrang L., Zhang H., Sahlberg B-L., Unge T., Loevgren S., Fridborg K., Baeckbro K. (1999), J. Med. Chem. 42: 4150.
5. Salyers A. A., Whitt D. D. (2001), Microbiology Diversity, Disease and the Environment, 1st Ed., Fitzgerald Science Press, Bethesda, Maryland, p. 382.
6. Katzung B. G. (2001), Basic and Clinical Pharmacology, 8th Ed., Lange Medical Books, McGraw-Hill, USA, p. 831.
7. Hoffman J. M., Wai J. S., Thomas C. M., Levin R. B., O'Brien J. A., Goldman M. E. (1992), J. Med. Chem. 35: 3784.
8. De Clercq E. (1999), Il Farmaco 54; 26.
9. Spence R. A., Kati W. M., Anderson K. S., Johnson K. A. (1995), Science 267: 988.
10. Myeck M. J., Harvey R. A., Champe, P. C. (2000), Pharmacology, 2nd Ed., Lippencott Williams & Wilkins, Philadelphia, p. 461.
11. Hirsch M. S. (1997), Antiviral Ther. 2: 19.
12. Saari W. S., Wai J. S., Fisher T. E., Thomas C. M., Hoffman J. M., Rooney C. S., Smith A. M., Johns A. H., Bamberger D. L., Goldman M. E., O'Brien J. A., Nunberg, J. H., Quintero J. C., Schleif W. A., Emini E. A., Anderson P. S. (1992), J. Med. Chem. 35: 3792.
13. Nofal Z. M., El-Zahar M. I., Abd El-Karim S. S. (2000), Molecules 5: 99.
14. Sener E. A., Bingoel K. K., Oeren I., Arpaci O. T., Yalcin, I., Altanlar N. (2000), Il Farmaco 55: 469.
15. Burkholder C. R., Dolbier W. R., Medebielle M. (2000), J. Flour. Chem. 102: 369.
16. Ranft D., Seyfarth T., Schaper K-J., Lehwark-Yvetot G., Bruhn C., Buege, A. (1999), Arch. Pharm. Pharm. Med. Chem. 332: 427.
17. Lecubin F., Fourrey J. L., Sun J-S, Benhida R. (1999), Nucleosides Nucleotides 18: 1609.
18. Van derpoorten K., Ucar H., Andrei G., Snoeck R., Balzarini, J., De Clercq E., Poupaert J. H. (1999), Antiviral Chem. Chemother. 10: 87.
19. Kappe C. O. (2000), Eur. J. Med. Chem. 35: 1043.
20. Pandeya S. N., Sriram D., Nath G., De Clercq E. (1999), Il Farmaco 54: 624.
21. Al-Soud Y. A., Al-Masoudi N. A. (1999), Arch. Pharm. Pharm. Med. Chem. 332: 143.
22. Badawey E. A. M., Kappe, T. (1997), Arch. Pharm. Pharm. Med. Chem. 330: 59.
23. Singh S. P., Prakash I., Tomer R. K., Prakash O. M., Sawhney S. N. (1983), Indian J. Chem. 22B: 37.
24. Dersch F., De Angelus M. R. (1962), U.S. 3,023,103, 1962; C.A. 57: 325h.
25. Garg H. G., Singh P. P. (1970), J. Chem. Soc. 656.
26. Vince R., Hua M., Brownell J., Daluge S., Lee, F., Shannon W. M., Lavelle G. C., Qualls J., Weislow O. S., Kiser R., Canonico P. G., Schultz R. H., Narayanan V. L., Mayo G., Shoemaker R. H., Boyd M. R. (1988), Biochem. Biophys. Res. Commun. 156: 1046.
27. Weislow O. S., Kiser R., Fine D. L., Bader J., Shoemaker R. H., Boyd M. R. (1989), J. Natl. Cancer Inst. 81: 577.